Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Oncology | Pharmacy | Institutional

Back to Journal Articles

Bosulif Approved for Chronic Myelogenous Leukemia

Last Updated: September 05, 2012.

 

Intended for chronic, accelerated or blast phase Philadelphia chromosome positive CML

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 

WEDNESDAY, Sept. 5 (HealthDay News) -- Bosulif (bosutinib) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML), the agency said in a news release.

Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib, the FDA said. Bosulif works by blocking the tyrosine kinase signal that promotes abnormal, unhealthy granulocyte development.

Bosulif was evaluated in a clinical trial that included 546 adults with CML. The drug's most common side effects included diarrhea, nausea, thrombocytopenia, abdominal pain, rash, anemia, fever, and fatigue.

The drug is marketed by Pfizer, based in New York City.

More information

To learn more about this approval, visit the FDA.

Copyright © 2012 HealthDay. All rights reserved.


Previous: World Cancer Congress, Aug. 27-30, 2012 Next: Less Pain After Hysterectomy With Vessel Sealing

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.